Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Tan Sheet

Executive Summary

Company's acquisition of 20% of Roche voting stock for $2.8 bil. is not expected to impact its nutritionals businesses, firm says. Calling move a long-term financial investment primarily involving its pharmaceutical operations, Novartis says Roche's position in bulk vitamin industry would not likely affect ReSource Wellness line or functional food strategy. Novartis is reviewing functional foods options after halting distribution of Aviva line in foreign markets due to lower-than-expected consumer reception. CFO Raymond Breu referred to firm's nutrition businesses as "farther away" from its core pharmaceutical goals at J.P. Morgan conference in late April (1"The Tan Sheet" May 7, p. 6)

You may also be interested in...

Novartis OTCs Fit Well With Pharma Core - CFO

Novartis' nutritional and eye care businesses are seen as "farther away" from the company's core pharmaceutical focus going forward, CFO Raymund Breu told a J.P. Morgan CEO conference on building shareholder value April 26.

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts